Hepatic Safety of Voriconazole after Allogeneic Hematopoietic Stem Cell Transplantation

Biology of Blood and Marrow Transplantation

Volumn 16, Issue 1, 2010, Pages 46-52

  Amigues, I ^a   Cohen, N ^a   Chung, D ^a   Seo, S K ^a   Plescia, C ^a   Jakubowski, A ^a   Barker, J ^a   Papanicolaou, Genovefa A ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Adverse reaction; Allogeneic stem cell transplantation; Hepatotoxicity; Liver function; Voriconazole

Indexed keywords

ACICLOVIR; ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ANABOLIC AGENT; ANTIFUNGAL AGENT; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOSPORIN A; DEFERASIROX; FLUCONAZOLE; MICAFUNGIN; ORAL CONTRACEPTIVE AGENT; PENICILLIN V POTASSIUM; PENTAMIDINE; RAPAMYCIN; TACROLIMUS; VORICONAZOLE;

ACUTE GRAFT VERSUS HOST DISEASE; ADOLESCENT; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALLOGRAFT; ARTICLE; CHILD; CONTROLLED STUDY; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG FATALITY; DRUG MONITORING; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HERPES SIMPLEX; HERPES ZOSTER; HUMAN; LIVER DYSFUNCTION; LIVER FAILURE; LIVER FUNCTION TEST; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MYCOSIS; PNEUMOCYSTIS PNEUMONIA; REFERENCE VALUE; RETROSPECTIVE STUDY; STREPTOCOCCUS PNEUMONIA; T CELL DEPLETION; TREATMENT DURATION;

ADULT; ANTIFUNGAL AGENTS; CHILD; COHORT STUDIES; DRUG MONITORING; DRUG-INDUCED LIVER INJURY; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LIVER; LIVER FUNCTION TESTS; LYMPHOCYTE DEPLETION; MALE; OPPORTUNISTIC INFECTIONS; PYRIMIDINES; RETROSPECTIVE STUDIES; RISK FACTORS; STATISTICS AS TOPIC; T-LYMPHOCYTES; TRIAZOLES;

EID: 72649102484     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2009.08.015     Document Type: Article

References (23)

1. Vfend package insert (2008), Pfizer Inc, New York
2. Zimmerman H. Expressions of hepatotoxicity. In: Zimmerman H. (Ed). Hepatotoxicity: The Adverse Effects of Drugs and Other Chemicals on the Liver. 2nd edition (1999), Lippincott, Williams & Wilkins, Philadelphia 61-109
3. Hamza N., Ghannoum M., and Lazarus H. Choices aplenty: antifungal prophylaxis in hematopoietic stem cell transplant recipients. Bone Marrow Transplant 34 (2004) 377-389
4. Grant S., and Clissold S. Fluconazole: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses. Drugs 39 (1990) 877-916
5. Bercoff E., Bernuau J., Degott C., et al. Ketoconazole-induced fulminant hepatitis. Gut 26 (1985) 636-638
6. Cauwenbergh G. Safety aspects of ketoconazole, the most commonly used systemic antifungal. Mycoses 32 Suppl 2 (1989) 59-63
7. Lavrijsen A., Balmus K., Nugteren-Huying W., et al. Hepatic injury associated with itraconazole. Lancet 340 (1992) 251-252
8. Stricker B., Blok A., Bronkhorst F., et al. Ketoconazole-associated hepatic injury: a clinicopathological study of 55 cases. J Hepatol 3 (1986) 399-406
9. Svejgaard E., and Ranek L. Hepatic dysfunction and ketoconazole therapy. Ann Internal Med 96 (1982) 788-789
10. Van Parys G., Evenepoel C., Van Damme B., et al. Ketoconazole-induced hepatitis: a case with a definite cause-effect relationship. Liver 7 (1987) 27-30
11. Van Puijenbroek E., Metselaar H., Berghuis P., et al. Acute hepatocytic necrosis during ketoconazole therapy for treatment of onychomycosis. National Foundation for Registry and Evaluation of Adverse Effects. Nederlands Tijdschrift voor Geneeskunde 142 (1998) 2416-2418 [in Dutch]
12. Wells C., and Lever A. Dose-dependent fluconazole hepatotoxicity proven on biopsy and rechallenge. J Infect 24 (1992) 111-112
13. Den Hollander J., Van Arkel C., Rijnders B., et al. Incidence of voriconazole hepatotoxicity during intravenous and oral treatment for invasive fungal infections. J Antimicrob Chemother 57 (2006) 1248-1250
14. Siwek G., Pfaller M., Polgreen P., et al. Incidence of invasive aspergillosis among allogeneic hematopoietic stem cell transplant patients receiving voriconazole prophylaxis. Diagn Microbiol Infect Dis 55 (2006) 209-212
15. Arai S., Lee L., and Vogelsang G. A systematic approach to hepatic complications in hematopoietic stem cell transplantation. J Hematother Stem Cell Res 11 (2002) 215-229
16. Kim C., Shin W., Sim S., et al. Liver disease during the first post-transplant year in bone marrow transplantation recipients: retrospective study. Bone Marrow Transplant 26 (2000) 193-197
17. Wingard J., and Leather H. Hepatotoxicity associated with antifungal therapy after bone marrow transplantation. Clin Infect Dis 41 (2005) 308-310
18. Johnson L., and Kauffman C. Voriconazole: a new triazole antifungal agent. Clin Infect Dis 36 (2003) 630-637
19. Denning D., Ribaud P., Milpied N., et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 34 (2002) 563-571
20. Lutsar I., Hodges M., Tomaszewski K., et al. Safety of voriconazole and dose individualization. Clin Infect Dis 36 (2003) 1087-1088
21. Pascual A., Calandra T., Bolay S., et al. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis 46 (2008) 201-211
22. Potoski B., and Brown J. The safety of voriconazole. Clin Infect Dis 35 (2002) 1273-1275
23. Trifilio S., Ortiz R., Pennick G., et al. Voriconazole therapeutic drug monitoring in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant 35 (2005) 509-513